Successful rechallenge with imatinib in a patient with chronic myeloid leukemia who previously experienced imatinib mesylate induced pneumonitis

Tuberculosis and Respiratory Diseases

Volumn 75, Issue 6, 2013, Pages 256-259

  Go, Seong Woo ^a   Kim, Boo Kyeong ^a   Lee, Sung Hak ^a   Kim, Tae Jung ^a   Huh, Joo Yeon ^a   Lee, Jong Min ^a   Hah, Jick Hwan ^a   Kim, Dong Whi ^a   Cho, Min Jung ^a   Kim, Tae Wan ^a   Kang, Ji Young ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Imatinib; Leukemia, Myelogenous, Chronic, BCR ABL Positive; Lung Diseases, Interstitial

Indexed keywords

IMATINIB; PREDNISOLONE; CARBON MONOXIDE;

ADULT; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN TISSUE; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; LUNG FUNCTION TEST; MALE; BRONCHOSCOPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; DRUG RECHALLENGE; DYSPNEA; EOSINOPHIL COUNT; LUNG LAVAGE; LUNG NODULE; LYMPHOCYTE COUNT; MACROPHAGE; NEUTROPHIL COUNT; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY; TREATMENT DURATION;

EID: 84946164191     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2013.75.6.256     Document Type: Article

References (11)

1. Deininger MW,Goldman JM,Melo JV, The molecular biology of chronic myeloid leukemia. Blood. 2000, 96, 3343-56.
2. Ohnishi K, Sakai F, Kudoh S, Ohno R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia 2006;20:1162-4.
3. Kim TH, Kim BG, Cho SW, Cho SK, Kim HJ, Yuh YJ, et al. Imatinib-mesylate induced interstitial pneumonitis in two CML patients. Tuberc Respir Dis 2011;71:210-5.
4. Lee JW, Kim HJ, Kim KJ, Shin KC, Hong YH, Chung JH, et al. A case of imatinib-mesylate associated hypersensitivity pneumonitis. Tuberc Respir Dis 2005;59:423-6.
5. Barber NA, Ganti AK. Pulmonary toxicities from targeted therapies: a review. Target Oncol 2011;6:235-43.
6. Yokoyama T, Miyazawa K, Kurakawa E, Nagate A, Shimamoto T, Iwaya K, et al. Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration. Leukemia 2004;18:645-6.
7. Snyder LS, Hertz MI, Peterson MS, Harmon KR, Marinelli WA, Henke CA, et al. Acute lung injury: pathogenesis of intraalveolar fibrosis. J Clin Invest 1991;88:663-73.
8. Walsh J, Absher M, Kelley J. Variable expression of platelet-derived growth factor family proteins in acute lung injury. Am J Respir Cell Mol Biol 1993;9:637-44.
9. Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 2000;20:1245-59.
10. Seki N, Ito A, Watanabe K, Shibakuki R, Seto T, Uematsu K, et al. Irreversible imatinib-induced pneumonitis following long-term imatinib administration. Intern Med 2007;46:1941-2.
11. Delomas T, Dar ne C, Besson C. Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib. Leuk Lymphoma 2012;53:332-3.